Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.18
$0.46
$17.51
$978.01M-0.1390,307 shs22,300 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.89
+0.6%
$26.57
$23.14
$30.93
$3.70B0.451.46 million shs32,446 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$29.56
+2.6%
$30.60
$21.51
$56.00
$3.56B0.911.35 million shs61,036 shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$34.31
-3.3%
$33.86
$16.01
$44.34
$3.82B0.99910,086 shs90,006 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
-1.69%+0.04%+2.14%+8.90%+5.11%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-1.13%+1.41%-20.53%+19.60%-26.15%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-2.61%+1.46%-6.90%+31.07%+104.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.7388 of 5 stars
0.00.00.04.80.60.80.6
Perrigo Company plc stock logo
PRGO
Perrigo
4.8354 of 5 stars
2.15.04.23.52.61.72.5
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.465 of 5 stars
4.50.00.00.03.30.80.0
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.3967 of 5 stars
3.45.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0022.72% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.06
Buy$65.59121.89% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.80
Moderate Buy$54.2858.19% Upside

Current Analyst Ratings Breakdown

Latest FIXX, RNA, PRGO, and ZLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$73.00 ➝ $75.00
6/27/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00
6/24/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
6/17/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
6/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$65.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $75.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.00
6/9/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $54.00
6/9/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $75.00
5/12/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$72.00 ➝ $68.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.16M0.00N/AN/A$1.26 per share0.00
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.85$4.99 per share5.39$31.66 per share0.85
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$8.93M399.06N/AN/A$11.94 per share2.48
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.55N/AN/A$7.68 per share4.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.79N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest FIXX, RNA, PRGO, and ZLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.42N/AN/AN/A$125.66 millionN/A
8/1/2025Q2 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.59N/AN/AN/A$1.08 billionN/A
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.31%N/AN/A 23 Years
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Latest FIXX, RNA, PRGO, and ZLAB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/A
7.25
7.25
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
16.91
16.91
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
31.32%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
16.10%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
758.13 million48.77 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.93 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million115.90 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869111.08 million105.57 millionOptionable

Recent News About These Companies

Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald
FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Homology Medicines stock logo

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.89 +0.15 (+0.56%)
As of 10:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$29.56 +0.76 (+2.64%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$34.31 -1.17 (-3.30%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.